Path: ...!news.roellig-ltd.de!open-news-network.org!weretis.net!feeder8.news.weretis.net!newsfeed.xs3.de!nntp-feed.chiark.greenend.org.uk!ewrotcd!news.killfile.org!news.eyrie.org!beagle.ediacara.org!.POSTED.beagle.ediacara.org!not-for-mail
From: RonO <rokimoto557@gmail.com>
Newsgroups: talk.origins
Subject: Conditional approval for an H5 vaccine for poultry
Date: Mon, 17 Feb 2025 08:37:23 -0600
Organization: A noiseless patient Spider
Lines: 24
Sender: to%beagle.ediacara.org
Approved: moderator@beagle.ediacara.org
Message-ID: <vovhj2$166c1$1@dont-email.me>
Reply-To: rokimoto557@gmail.com
MIME-Version: 1.0
Content-Type: text/plain; charset=UTF-8; format=flowed
Content-Transfer-Encoding: 7bit
Injection-Info: beagle.ediacara.org; posting-host="beagle.ediacara.org:3.132.105.89";
	logging-data="29353"; mail-complaints-to="usenet@beagle.ediacara.org"
User-Agent: Mozilla Thunderbird
To: talk-origins@moderators.isc.org
Cancel-Lock: sha1:zQLCwmd2urwTrQA7XNDjRT0KZ+o=
Return-Path: <news@eternal-september.org>
X-Original-To: talk-origins@ediacara.org
Delivered-To: talk-origins@ediacara.org
	id 9FEC122978C; Mon, 17 Feb 2025 09:37:33 -0500 (EST)
	by beagle.ediacara.org (Postfix) with ESMTPS id 6AB0F229783
	for <talk-origins@ediacara.org>; Mon, 17 Feb 2025 09:37:31 -0500 (EST)
          by moderators.individual.net (Exim 4.98)
          for talk-origins@moderators.isc.org with esmtps (TLS1.3)
          tls TLS_AES_256_GCM_SHA384
          (envelope-from <news@eternal-september.org>)
          id 1tk2FT-000000022Dd-0AF8; Mon, 17 Feb 2025 15:37:27 +0100
	(using TLSv1.3 with cipher TLS_AES_256_GCM_SHA384 (256/256 bits)
	 key-exchange X25519 server-signature ECDSA (P-256) server-digest SHA256)
	(No client certificate requested)
	by smtp.eternal-september.org (Postfix) with ESMTPS id BE3276060D
	for <talk-origins@moderators.isc.org>; Mon, 17 Feb 2025 14:37:23 +0000 (UTC)
Authentication-Results: name/BE3276060D; dmarc=fail (p=none dis=none) header.from=gmail.com
	id 62B78DC01CA; Mon, 17 Feb 2025 15:37:23 +0100 (CET)
X-Injection-Date: Mon, 17 Feb 2025 15:37:23 +0100 (CET)
Content-Language: en-US
X-Auth-Sender: U2FsdGVkX19YO6nSNTKZxyssD2BEv+xCYQ5noVNPd/0=
	FREEMAIL_FORGED_REPLYTO,FREEMAIL_REPLYTO_END_DIGIT,
	HEADER_FROM_DIFFERENT_DOMAINS,NML_ADSP_CUSTOM_MED,
	RCVD_IN_DNSWL_BLOCKED,RCVD_IN_VALIDITY_CERTIFIED_BLOCKED,
	RCVD_IN_VALIDITY_RPBL_BLOCKED,SPF_HELO_NONE,SPF_PASS,URIBL_BLOCKED,
	USER_IN_WELCOMELIST,USER_IN_WHITELIST autolearn=ham autolearn_force=no
	version=3.4.6
	smtp.eternal-september.org
Bytes: 4106

https://www.science.org/content/article/u-s-conditionally-approves-vaccine-protect-poultry-avian-flu

The vaccine is to a reassorted virus H5N2, but is claimed to have been 
designed to work against the current H5N1 wild avian virus.  Both the 
B3.13 and the D1.1 genotypes have the H5 gene clade 2.3.4.4b, but their 
H5 sequences are very different from the H5 sequence that gave the clade 
it's designation in Asia.  By the time the Missouri patient had been 
infected in October the H5 sequence had changed enough from the B3.13 
genotype that the original H5 antigen that came from the first infected 
dairy worker in Texas was believed to not be effectively neutralized by 
the antibodies that would be circulating in the Missouri patient, and 
they made a synthetic H5 antigen sequence with the sequence of the virus 
isolated from the Missouri patient in order to test for antibodies in 
their blood.  They identified H5 antigens, but 2 of the 3 antibody tests 
failed for both Missouri cases infected with the dairy virus.

This just means that before this vaccine is used they need to determine 
if it is effective against the current circulating B3.13 and D1.1 H5N1 
virus genotypes.  My take is that the current D1.1 genotype is starting 
to reinfect dairy herds that had already been infected by the B3.13 
virus in Nevada, so they likely need a bivalent vaccine that works 
against both genotypes now infecting poultry flocks and dairy herds.

Ron Okimoto